BioSpace6d
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...
FierceBiotech7d
Lonza's Synaffix adds Boehringer to its constellation of partners with $1.3B ADC tech pact
Under a new licensing pact, Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an "agreed but undisclosed number of targets." The first target was decided by the ...
Sutro Biopharma, Boehringer announce application of Sutro’s technology
Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro’s proprietary cell-free expression ...
Contract Pharma7d
Boehringer Ingelheim Licenses Synaffix ADC Technology
Boehringer Ingelheim has licensed Synaffix B.V.’s ADC technology, significantly bolstering its ADC portfolio with the goal of ...
pharmaphorum9d
WCLC: Bayer, Boehringer face off on HER2 cancers
Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...
pharmaphorum1d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...